Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

Prudhvi Regula; David Rosenstreich; Elina Jerschow; Manish Ramesh; Denisa Ferastraoaru; Jessica Oh; Daniella S Aivazi; Jonathan M Aivazi; Golda Hudes

doi:10.1016/j.jacig.2022.04.005

Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

J Allergy Clin Immunol Glob. 2022 Aug;1(3):175-177. doi: 10.1016/j.jacig.2022.04.005. Epub 2022 Apr 30.

Authors

Prudhvi Regula¹, David Rosenstreich¹, Elina Jerschow¹, Manish Ramesh¹, Denisa Ferastraoaru¹, Jessica Oh¹, Daniella S Aivazi², Jonathan M Aivazi³, Golda Hudes¹

Affiliations

¹ Division of Allergy and Immunology, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.
² CUNY School of Medicine, the Sophie Davis School of Biomedical Education Program, New York, NY.
³ the New York Institute of Technology College of Osteopathic Medicine, Glen Head, NY.

Abstract

Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.

Keywords: COVID-19 vaccines; COVID-19, Coronavirus disease 2019; Graded dosing of vaccine; PEG, Polyethylene glycol; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; mRNA vaccine allergy; vaccine desensitization; vaccine hesitancy.

Publication types

Case Reports